Copy to clipboard 
NuVasive reported 4Q21 orthopedic sales of $302.1 million, +3.5% vs. 4Q20. For the full year 2021, the company posted $1.1 billion in orthopedic sales, +8.4% vs. 2020. Compared to 2019, NuVasive slid -2.5%.
The company made headway in growing its presence in subsegments of spine where it had been traditionally underrepresented. NuVasive’s investment in the cervical spine space brought double-digit growth for its C360 portfolio both for the quarter and year, driven by the Simplify cervical disc and a new anterior column plating system.
The fourth quarter also gave NuVasive its first full quarter with the commercialized Pulse system. Pulse exceeded the company’s initial $5 million sales expectation for 2021. However, the company said that it is too early to determine the extent of the implant pull-through opportunity.
NuVasive CEO Chris Barry said of the company’s transformation, “The evolution of the company has been from an early stage disruptor with XLIF to a comprehensive spine player. We are not moving away from our leadership position in anterior. We’re complementing that with posterior, cervical and introducing enabling tech to complement our broader portfolio.”
The company expects 2022 orthopedic sales growth of +5% to +8%. The broad range reflects NuVasive’s confidence in its growing portfolio against the backdrop of uncertainty brought on by supply chain issues, inflation and hospital staffing shortages.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $262.3 | $253.2 | $9.2 | 3.6% |
| Trauma | $14.0 | $13.1 | $0.9 | 6.9% |
| Orthobiologics | $25.7 | $25.5 | $0.2 | 0.7% |
| Total | $302.1 | $291.8 | $10.3 | 3.5% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $995.0 | $914.3 | $80.7 | 8.8% |
| Trauma | $48.7 | $45.7 | $3.0 | 6.5% |
| Orthobiologics | $95.3 | $90.5 | $4.8 | 5.3% |
| Total | $1,139.0 | $1,050.6 | $88.4 | 8.4% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $231.8 | $224.2 | $7.5 | 3.4% |
| OUS | $70.3 | $67.6 | $2.7 | 4% |
| EMEA | $46.0 | $43.9 | $2.1 | 4.7% |
| Asia Pacific | $18.8 | $17.6 | $1.3 | 7.2% |
| Rest of World | $5.5 | $6.1 | ($0.6) | (9.8%) |
| Total | $302.1 | $291.8 | $10.3 | 3.5% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $876.6 | $821.8 | $54.8 | 6.7% |
| OUS | $262.4 | $228.8 | $33.6 | 14.7% |
| EMEA | $171.1 | $148.9 | $22.3 | 15% |
| Asia Pacific | $69.1 | $58.9 | $10.2 | 17.3% |
| Rest of World | $22.1 | $21.0 | $1.2 | 5.6% |
| Total | $1,139.0 | $1,050.6 | $88.4 | 8.4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $302.7 | |
| Cost of Sales | $83.5 | 27.6% |
| R & D | $160.7 | 53.1% |
| Selling and Admin | $25.2 | 8.3% |
| Other | $70.0 | 23.1% |
| Net Earnings | ($36.7) | (12.1%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
NuVasive reported 4Q21 orthopedic sales of $302.1 million, +3.5% vs. 4Q20. For the full year 2021, the company posted $1.1 billion in orthopedic sales, +8.4% vs. 2020. Compared to 2019, NuVasive slid -2.5%.
The company made headway in growing its presence in subsegments of spine where it had been traditionally underrepresented. NuVasive's...
NuVasive reported 4Q21 orthopedic sales of $302.1 million, +3.5% vs. 4Q20. For the full year 2021, the company posted $1.1 billion in orthopedic sales, +8.4% vs. 2020. Compared to 2019, NuVasive slid -2.5%.
The company made headway in growing its presence in subsegments of spine where it had been traditionally underrepresented. NuVasive’s investment in the cervical spine space brought double-digit growth for its C360 portfolio both for the quarter and year, driven by the Simplify cervical disc and a new anterior column plating system.
The fourth quarter also gave NuVasive its first full quarter with the commercialized Pulse system. Pulse exceeded the company’s initial $5 million sales expectation for 2021. However, the company said that it is too early to determine the extent of the implant pull-through opportunity.
NuVasive CEO Chris Barry said of the company’s transformation, “The evolution of the company has been from an early stage disruptor with XLIF to a comprehensive spine player. We are not moving away from our leadership position in anterior. We’re complementing that with posterior, cervical and introducing enabling tech to complement our broader portfolio.”
The company expects 2022 orthopedic sales growth of +5% to +8%. The broad range reflects NuVasive’s confidence in its growing portfolio against the backdrop of uncertainty brought on by supply chain issues, inflation and hospital staffing shortages.
Orthopedic Sales Data
All orthopedic sales data is provided in USD millions unless otherwise noted. Orthopedic sales and growth rates are estimated on an as-reported basis.
Orthopedic Sales by Segment
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $262.3 | $253.2 | $9.2 | 3.6% |
| Trauma | $14.0 | $13.1 | $0.9 | 6.9% |
| Orthobiologics | $25.7 | $25.5 | $0.2 | 0.7% |
| Total | $302.1 | $291.8 | $10.3 | 3.5% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| Spine | $995.0 | $914.3 | $80.7 | 8.8% |
| Trauma | $48.7 | $45.7 | $3.0 | 6.5% |
| Orthobiologics | $95.3 | $90.5 | $4.8 | 5.3% |
| Total | $1,139.0 | $1,050.6 | $88.4 | 8.4% |
Orthopedic Sales by Geography
| 4Q21 | 4Q20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $231.8 | $224.2 | $7.5 | 3.4% |
| OUS | $70.3 | $67.6 | $2.7 | 4% |
| EMEA | $46.0 | $43.9 | $2.1 | 4.7% |
| Asia Pacific | $18.8 | $17.6 | $1.3 | 7.2% |
| Rest of World | $5.5 | $6.1 | ($0.6) | (9.8%) |
| Total | $302.1 | $291.8 | $10.3 | 3.5% |
| FY21 | FY20 | $ Chg | % Chg | |
|---|---|---|---|---|
| US | $876.6 | $821.8 | $54.8 | 6.7% |
| OUS | $262.4 | $228.8 | $33.6 | 14.7% |
| EMEA | $171.1 | $148.9 | $22.3 | 15% |
| Asia Pacific | $69.1 | $58.9 | $10.2 | 17.3% |
| Rest of World | $22.1 | $21.0 | $1.2 | 5.6% |
| Total | $1,139.0 | $1,050.6 | $88.4 | 8.4% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $302.7 | |
| Cost of Sales | $83.5 | 27.6% |
| R & D | $160.7 | 53.1% |
| Selling and Admin | $25.2 | 8.3% |
| Other | $70.0 | 23.1% |
| Net Earnings | ($36.7) | (12.1%) |
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
